Chemiluminescence Immunoassay Analyzers Market Size Worth USD 9.7 Billion in 2032 | Emergen Research
18. Dezember 2023 06:54 ET
|
Emergen Research
Vancouver, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The global Chemiluminescence Immunoassay (CLIA) analyzers market size was USD 5.42 Billion in 2022 and is expected to register rapid revenue CAGR of 6.0%...
Crinetics to Highlight Broad Pipeline at ENDO 2023
09. Juni 2023 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the...
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
05. Januar 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
25. Oktober 2021 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting
27. September 2021 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company...
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
16. Juni 2021 08:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
06. Mai 2021 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics...
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
16. November 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
13. November 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
04. September 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...